TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22107076

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Mental activity intervention
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Coping plans
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Coping plans in exercise condition
Number of subjects: 171
Study: 20234892

Group type: EXPERIMENTAL
Intervention: Prime and Bond adhesive using the immediate dentin sealing (IDS) technique
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated teeth)
Number of subjects: 25
Study: 18661687

Group type: EXPERIMENTAL
Intervention: 12.5 mg of HBB plus 2.5 microg of intrathecal sufentanil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 12.5 mg of HBB plus 5 microg of intrathecal sufentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: 12.5 mg of HBB
Number of subjects: 100

Group type: COMPARATOR
Intervention: 12.5 mg of HBB plus 5 microg of subcutaneous sufentanil
Number of subjects: 100
Study: 15968954

Group type: EXPERIMENTAL
Intervention: 40 microg intramuscular hepatitis B vaccine (group 1)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 20 microg intradermal hepatitis B vaccine (group 2)
Number of subjects: 86
Study: 12697108

Group type: EXPERIMENTAL
Intervention: Comprehensive prevention of cerebrovascular diseases (1987 - 2000)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cohort (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 10231930

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) and serum prostate specific antigen (PSA) > 4.0 ng/ml
Number of subjects: 12542

Group type: COMPARATOR
Intervention: Digital rectal examination (DRE) alone
Number of subjects: 12542
Study: 8910238

Group type: EXPERIMENTAL
Intervention: P40 component presence
Number of subjects: 145
Study: 1423942

Group type: EXPERIMENTAL
Intervention: Candoxatril 25 mg every 12 hours (group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Candoxatril 100 mg every 12 hours (group 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3883066

Group type: EXPERIMENTAL
Intervention: One-day surgery for tubal ligation
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: One-day surgery for hernia repair
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: One-day surgery for meniscectomy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Inpatient surgery
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: One-day surgery
Number of subjects: 182

Group type: COMPARATOR
Intervention: One-day surgery and inpatient care
Number of subjects: 182
Study: 30796651

Group type: EXPERIMENTAL
Intervention: MammaPrint® (MP)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BluePrint®
Number of subjects: 452
Study: 28887068

Group type: EXPERIMENTAL
Intervention: Rehabilitation services targeting physical impairments and immobility via the TCM‐RS
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: TCM‐RS plus conventional TCM pain management (TCM‐RS+Pain)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 516
Study: 27054824

Group type: EXPERIMENTAL
Intervention: Therapist-reported alliance in alliance-focused therapy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Patient-reported alliance
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Therapist-reported alliance
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pooled level of alliance from both partners
Number of subjects: 241
Study: 24491134

Group type: EXPERIMENTAL
Intervention: Movement as Medicine for Type 2 Diabetes intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 0
Study: 22407494

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 52
Study: 20039105

Group type: EXPERIMENTAL
Intervention: Pramipexole slow-release formulations
Number of subjects: 15

Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation
Number of subjects: 15
Study: 17681969

Group type: EXPERIMENTAL
Intervention: sublingual oxybutynin 5 mg every 8 h during the 24 h after surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo every 8 h during the 24 h after surgery
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: sublingual oxybutynin 5 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 16185789

Group type: EXPERIMENTAL
Intervention: Calshake
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ensure plus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fortijuce
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calshake (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall preference after chemotherapy
Number of subjects: 60
Study: 11809169

Group type: EXPERIMENTAL
Intervention: Magnetization transfer (MT) and diffusion tensor (DT) magnetic resonance imaging (MRI) in fatigued patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Magnetization transfer (MT) and diffusion tensor (DT) magnetic resonance imaging (MRI) in non-fatigued patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fatigue severity scale scores in fatigued patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fatigue severity scale scores in non-fatigued patients
Number of subjects: 28
Study: 10364025

Group type: EXPERIMENTAL
Intervention: Rectal isobaric distension (tonic mode)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rectal isobaric distension (phasic mode)
Number of subjects: 51
Study: 7734251

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 100
Study: 2040934

Group type: EXPERIMENTAL
Intervention: Ibuprofen (300 mg for the first month, 400 mg for the second month, 600 mg for the third month)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ibuprofen (13.4 +/- 4.1 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7075655

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg and codeine phosphate 60 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30928823

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/day)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 29986902

Group type: EXPERIMENTAL
Intervention: Bobath plus dry needling
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bobath only
Number of subjects: 26
Study: 27625743

Group type: EXPERIMENTAL
Intervention: Pharmacist-provided telephonic medication therapy management (MTM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study: 25046167

Group type: EXPERIMENTAL
Intervention: Ponesimod 10-100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ponesimod 60-80 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ponesimod 40 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 16
Study: 22933494

Group type: EXPERIMENTAL
Intervention: Oxidised zirconium (OxZr) femoral component
Number of subjects: 331

Group type: COMPARATOR
Intervention: Cobalt-chromium (CoCr) femoral component
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Both OxZr and CoCr femoral components
Number of subjects: 331
Study: 20105318

Group type: EXPERIMENTAL
Intervention: Patient group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician group
Number of subjects: 0
Study: 17925136

Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with supervised exercises
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 102
Study: 16301359

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12085184

Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 104

Group type: COMPARATOR
Intervention: methotrexate and 5‐fluorouracil
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: low microvessel density
Number of subjects: 104
Study: 9451311

Group type: EXPERIMENTAL
Intervention: port/bag
Number of subjects: 208

Group type: COMPARATOR
Intervention: cap/bottle
Number of subjects: 208
Study: 7889180

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Continuous estrogen/progestogen
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Nonfractured women (control group)
Number of subjects: 116
Study: 2692687

Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus long-acting propranolol (80 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus long-acting propranolol (160 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bendrofluazide alone
Number of subjects: 23
Study: 358658

Group type: EXPERIMENTAL
Intervention: Lonazolac
Number of subjects: 2

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Oxyphenbutazone
Number of subjects: 2
Study: 31044536

Group type: EXPERIMENTAL
Intervention: Young adult DBT programme
Number of subjects: 37

Group type: COMPARATOR
Intervention: General adult DBT programme
Number of subjects: 37
Study: 30606198

Group type: EXPERIMENTAL
Intervention: TREAT format (structured journal club)
Number of subjects: 19
Study: 28736322

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Enzalutamide (high volume disease)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Enzalutamide (low volume disease)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 25818060

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone plus standard medical management
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Opioid agonist therapy
Number of subjects: 375

Group type: COMPARATOR
Intervention: No agonist therapy
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Engagement in agonist therapy
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Follow-up study participants
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Lifetime history of heroin use
Number of subjects: 375
Study: 23633201

Group type: EXPERIMENTAL
Intervention: Oral mixed meal test (MMT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Gastrostomy mixed meal test (MMT)
Number of subjects: 4
Study: 22029232

Group type: EXPERIMENTAL
Intervention: Clindamycin hydrochloride (test formulation)
Number of subjects: 32
Study: 19809225

Group type: EXPERIMENTAL
Intervention: 1-minute phenol application
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 2-minute phenol application
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 3-minute phenol application
Number of subjects: 110
Study: 16965992

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15559215

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus ASA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11837878

Group type: EXPERIMENTAL
Intervention: Pipe organs
Number of subjects: 43

Group type: COMPARATOR
Intervention: Digital organs
Number of subjects: 43
Study: 9163933

Group type: EXPERIMENTAL
Intervention: Induced depressive mood state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7960211

Group type: EXPERIMENTAL
Intervention: Isotretinoin (3 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Isotretinoin (9 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Beta-carotene (9 months)
Number of subjects: 57
Study: 2897517

Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG) given intramuscularly before and 1 week after transfusion
Number of subjects: 291

Group type: COMPARATOR
Intervention: No additional protection (Control)
Number of subjects: 291
Study: 29229430

Group type: EXPERIMENTAL
Intervention: Proactive Self-Management Program for Effects of Cancer Treatment (PROSPECT), 8 weeks duration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 27297426

Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with extra-virgin olive oil (EVOO)
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with tree nuts
Number of subjects: 2453

Group type: COMPARATOR
Intervention: MedDiet + EVOO
Number of subjects: 2453
Study: 25704601

Group type: COMPARATOR
Intervention: pantoprazole for 45 days
Number of subjects: 14
Study: 22728166

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamins E 1200 IU and C 1000 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 20698249

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30mg/day) plus polaprezinc (150mg/day)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Lansoprazole (30mg/day)
Number of subjects: 163
Study: 18390985

Group type: EXPERIMENTAL
Intervention: DC-ICD
Number of subjects: 334

Group type: COMPARATOR
Intervention: SC-ICD
Number of subjects: 334

Group type: COMPARATOR
Intervention: SC-simulated
Number of subjects: 334
Study: 16908620

Group type: EXPERIMENTAL
Intervention: Erythropoietin (400 U/kg 3 times per week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo/control
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythropoietin concentrations > or = 500 mU/mL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythropoietin concentrations < 500 mU/mL
Number of subjects: 16
Study: 15645891

Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Supreme (14% hydrogen peroxide, 100 mg on maxillary strip), used twice daily for 30 minutes for 6 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Supreme (14% hydrogen peroxide, 100 mg on maxillary strip), used twice daily for 30 minutes for 3 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11440089

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS)
Number of subjects: 0
Study: 9354312

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8438847

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg in the morning for 2 weeks, followed by 20 mg for an additional 4 weeks if unhealed.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Ranitidine 300 mg at night for 2 weeks, followed by open treatment with omeprazole if unhealed.
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg treatment.
Number of subjects: 241
Study: 3320390

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (UK) therapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 30905643

Group type: EXPERIMENTAL
Intervention: 6.0 mg faricimab
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 1.5 mg faricimab
Number of subjects: 229

Group type: COMPARATOR
Intervention: 0.3 mg ranibizumab
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Faricimab (both doses)
Number of subjects: 229
Study: 29357330

Group type: EXPERIMENTAL
Intervention: Lidocaine plus triamcinolone (TA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 48
Study: 27178725

Group type: EXPERIMENTAL
Intervention: PET-DCT
Number of subjects: 153

Group type: COMPARATOR
Intervention: DCT
Number of subjects: 153
Study: 24630387

Group type: EXPERIMENTAL
Intervention: Echocardiography-guided LV lead placement
Number of subjects: 183

Group type: COMPARATOR
Intervention: Routine strategy
Number of subjects: 183
Study: 22621656

Group type: EXPERIMENTAL
Intervention: t‐PA and DNase
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DNase
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 145
Study: 20660037

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg iv) alone and in combination with breakfast (550 kcal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Meal intake (550 kcal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg iv) in combination with breakfast (550 kcal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (isotonic saline) alone and in combination with breakfast
Number of subjects: 16
Study: 18815247

Group type: EXPERIMENTAL
Intervention: Tool A training with error-clamp trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tool B exposure after tool A training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Error-clamp trials after A+B training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tracking memory of tool B over time
Number of subjects: 0
Study: 16312918

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 90
Study: 12190903

Group type: EXPERIMENTAL
Intervention: Labial infiltration of 1.0 mL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lingual infiltration of 1.0 mL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined labial and lingual infiltration (0.5 mL each)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intraligamentary injection (118 mL, 2% lidocaine with 1:80,000 adrenaline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intraligamentary injection
Number of subjects: 12

Group type: COMPARATOR
Intervention: Buccal infiltrations
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lingual infiltrations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intraligamentary injections
Number of subjects: 12
Study: 9706923

Group type: EXPERIMENTAL
Intervention: Betamethasone 12 mg i.m. 30 min before surgery (Group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (saline) (Group P)
Number of subjects: 78
Study: 7843443

Group type: EXPERIMENTAL
Intervention: Short GnRH agonist protocol (900 micrograms/d buserelin acetate intranasally from day 1, followed by hMG from day 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: hMG administration from day 3 of the menstrual cycle (control group)
Number of subjects: 80
Study: 2132417

Group type: EXPERIMENTAL
Intervention: 100 W exercise treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 175 W exercise treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 9
Study: 927305

Group type: EXPERIMENTAL
Intervention: Drug B (Dihydrocodeine, Remedacen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug A (Codeine, Phenyltoloxamine)
Number of subjects: 0
Study: 30640308

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Warm-up (IMW)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham IMW (CON)
Number of subjects: 17
Study: 31999170

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT) group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Episodic Recent Thinking (ERT) control group
Number of subjects: 200
Study: 31219000

Group type: EXPERIMENTAL
Intervention: Pentavalent antimony (Sbv) + Pentoxifylline (PTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentavalent antimony (Sbv)
Number of subjects: 0
Study: 28814096

Group type: EXPERIMENTAL
Intervention: Single-shot popliteal fossa block (PFB)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Ankle block (AB)
Number of subjects: 167
Study: 25144134

Group type: EXPERIMENTAL
Intervention: Lower body strength (LBS) group performing resistance and power-oriented training (full squat, split squat, CMJ loaded, CMJ) twice per week in addition to in-water training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (C) doing in-water training only
Number of subjects: 21
Study: 23937552

Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic surgery (SILS)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Multiport laparoscopic surgery (MLS)
Number of subjects: 149
Study: 22036640

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided aspiration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoroscopic-guided aspiration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of ultrasound-guided aspiration and C-reactive protein
Number of subjects: 60
Study: 19255036

Group type: EXPERIMENTAL
Intervention: Head cooling for 72 hours starting within 6 hours of birth, rectal temperature maintained at 34.5 degrees C +/- 0.5 degrees C
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 230
Study: 17605489

Group type: EXPERIMENTAL
Intervention: Onplant installation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Orthosystem implant installation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Premolar extraction
Number of subjects: 120
Study: 14716650

Group type: EXPERIMENTAL
Intervention: PCA plus TENS
Number of subjects: 3

Group type: COMPARATOR
Intervention: PCA plus sham TENS
Number of subjects: 3

Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 3
Study: 11226108

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 40
Study: 9552948

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (current medical treatment)
Number of subjects: 56
Study: 7798982

Group type: EXPERIMENTAL
Intervention: Milan Overall Dementia Assessment (MODA)
Number of subjects: 312
Study: 3393937

Group type: EXPERIMENTAL
Intervention: Intercessory prayer (IP) by participating Christians praying outside the hospital
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control group (no intercessory prayer)
Number of subjects: 393